BioVaxys Technology Corp.

BioVaxys acquires TAETSoftware to utilize Trial Adverse Events Tracker platform

12:09 p.m. March 17, 2023

- News Direct

The Power Play by The Market Herald Releases New Interviews with Spey Resources, Melkior Resources and BioVaxys Technology Discussing Their Latest News

2:06 p.m. March 16, 2023

- ACCESSWIRE

The Power Play by The Market Herald Releases New Interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology Discussing Their Latest News

3:28 p.m. Dec. 20, 2022

- ACCESSWIRE

BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps

8:00 a.m. Dec. 19, 2022

- PR Newswire - PRF

BioVaxys Co-Founder, President and Chief Operating Officer Kenneth Kovan to Present at MedInvest Oncology Investor Conference

9:00 a.m. Dec. 5, 2022

- PR Newswire - PRF

Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

9:46 a.m. Dec. 1, 2022

- Financial News Media

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

9:21 a.m. Dec. 1, 2022

- Financial News Media

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

9:00 a.m. Dec. 1, 2022

- PR Newswire - PRF

BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021

9:00 a.m. Nov. 16, 2022

- PR Newswire - PRF

The Power Play by The Market Herald Releases New Interviews with RDARS, Infinity Stone Ventures, BioVaxys Technology, and Sitka Gold Discussing Their Latest News

2:33 p.m. Oct. 6, 2022

- ACCESSWIRE

Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027

8:47 a.m. Oct. 6, 2022

- Financial News Media

Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027

8:45 a.m. Oct. 6, 2022

- PR Newswire - PRF

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

8:22 a.m. Oct. 6, 2022

- Financial News Media

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

8:00 a.m. Oct. 6, 2022

- PR Newswire - PRF

The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News

2:28 p.m. Sept. 28, 2022

- ACCESSWIRE

BioVaxys Further Expands Vaccines Intellectual Property Portfolio

8:00 a.m. Sept. 28, 2022

- PR Newswire - PRF

BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in vivo animal study

8:00 a.m. Sept. 6, 2022

- PR Newswire - PRF

BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

4:18 a.m. Aug. 26, 2022

- PR Newswire - PRF

BIOVAXYS ANNOUNCES WARRANT EXTENSION

8:03 p.m. Aug. 9, 2022

- PR Newswire - PRF

Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development

8:00 a.m. June 15, 2022

- PR Newswire - PRF